Jinhe Biotechnology Past Earnings Performance
Past criteria checks 4/6
Jinhe Biotechnology's earnings have been declining at an average annual rate of -19.3%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 5% per year. Jinhe Biotechnology's return on equity is 3.7%, and it has net margins of 4.3%.
Key information
-19.3%
Earnings growth rate
-25.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 5.0% |
| Return on equity | 3.7% |
| Net Margin | 4.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Jinhe Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,262 | 97 | 380 | 85 |
| 30 Jun 24 | 2,207 | 88 | 382 | 80 |
| 31 Mar 24 | 2,166 | 95 | 379 | 78 |
| 31 Dec 23 | 2,174 | 86 | 374 | 74 |
| 30 Sep 23 | 2,060 | 76 | 391 | 72 |
| 30 Jun 23 | 2,030 | 78 | 376 | 75 |
| 31 Mar 23 | 2,130 | 81 | 363 | 78 |
| 01 Jan 23 | 2,123 | 76 | 354 | 82 |
| 30 Sep 22 | 2,272 | 86 | 329 | 78 |
| 30 Jun 22 | 2,242 | 78 | 328 | 76 |
| 31 Mar 22 | 2,136 | 56 | 315 | 74 |
| 01 Jan 22 | 2,078 | 94 | 318 | 72 |
| 30 Sep 21 | 2,046 | 126 | 316 | 70 |
| 30 Jun 21 | 1,927 | 125 | 310 | 69 |
| 31 Mar 21 | 1,844 | 133 | 318 | 69 |
| 31 Dec 20 | 1,815 | 117 | 309 | 66 |
| 30 Sep 20 | 1,741 | 144 | 309 | 63 |
| 30 Jun 20 | 1,797 | 175 | 301 | 62 |
| 31 Mar 20 | 1,831 | 201 | 303 | 56 |
| 31 Dec 19 | 1,782 | 185 | 305 | 61 |
| 30 Sep 19 | 1,767 | 178 | 327 | 60 |
| 30 Jun 19 | 1,759 | 183 | 339 | 51 |
| 31 Mar 19 | 1,676 | 171 | 331 | 50 |
| 31 Dec 18 | 1,629 | 164 | 316 | 41 |
| 30 Sep 18 | 1,603 | 138 | 319 | 37 |
| 30 Jun 18 | 1,521 | 117 | 273 | 54 |
| 31 Mar 18 | 1,457 | 98 | 275 | 43 |
| 31 Dec 17 | 1,458 | 108 | 275 | 34 |
| 30 Sep 17 | 1,414 | 140 | 242 | 21 |
| 30 Jun 17 | 1,440 | 147 | 272 | 0 |
| 31 Mar 17 | 1,486 | 155 | 266 | 0 |
| 31 Dec 16 | 1,496 | 164 | 255 | 0 |
| 30 Sep 16 | 1,450 | 159 | 237 | 0 |
| 30 Jun 16 | 1,396 | 148 | 223 | 0 |
| 31 Mar 16 | 1,315 | 132 | 201 | 0 |
| 31 Dec 15 | 1,250 | 105 | 192 | 0 |
| 30 Sep 15 | 1,143 | 84 | 182 | 0 |
| 30 Jun 15 | 1,030 | 79 | 154 | 0 |
| 31 Mar 15 | 956 | 80 | 144 | 0 |
| 31 Dec 14 | 840 | 77 | 142 | 0 |
| 30 Sep 14 | 771 | 87 | 141 | 0 |
| 30 Jun 14 | 765 | 95 | 133 | 0 |
| 31 Mar 14 | 756 | 93 | 132 | 0 |
| 31 Dec 13 | 741 | 90 | 126 | 0 |
Quality Earnings: 002688 has high quality earnings.
Growing Profit Margin: 002688's current net profit margins (4.3%) are higher than last year (3.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002688's earnings have declined by 19.3% per year over the past 5 years.
Accelerating Growth: 002688's earnings growth over the past year (27.5%) exceeds its 5-year average (-19.3% per year).
Earnings vs Industry: 002688 earnings growth over the past year (27.5%) exceeded the Pharmaceuticals industry -2.5%.
Return on Equity
High ROE: 002688's Return on Equity (3.7%) is considered low.